The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Analysis of the QuANTUM-First phase 3 trial found that the impact of quizartinib on patient-reported outcomes and health-related quality of life (QoL) were equivalent to a placebo, based on the European Organisation for Research and Treatment of Cancer 30-item Core QoL Questionnaire.
When multiple myeloma and chronic lymphocytic leukemia appear in the same patient, they do not derive from the same B-cell but rather develop independently from separate B-cells.
The US Food and Drug Administration has approved the checkpoint inhibitor nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients who are 12 years and older and have previously untreated stage III or IV classical Hodgkin lymphoma.
The chimeric antigen receptor T-cell therapy zamtocabtagene autoleucel (zamto-cel) showed encouraging activity and a favorable safety profile in patients with relapsed or refractory diffuse large
Andrew Lane, MD, PhD, of Dana Farber Cancer Institute, reports the results from a phase 2 trial in tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy in blastic plasmacytoid dendritic cell neoplasms.
To access the SOHO Career Center click the following link.
